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Abstract
Anti-neutrophil cytoplasmic antibodies (ANCA) have become important diagnostic markers of
small vessel vasculitides characterized by focal necrotizing lesions of vessel walls and
accumulation of lymphocytes and macrophages around the affected vessels. IgG class
ANCA directed to proteinase 3 (PR3) of neutrophils and monocytes seem to be directly
involved in the pathophysiology of vascular damage by causing excessive neutrophil activation
and vessel wall destruction. PR3 and elastase are important players in the mechanisms of
vascular necrosis. Methods of detecting ANCA have now been defined but are not uniformly
used, even though clinical decisions heavily depend on correct ANCA results.
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ANCA = anti-neutrophil cytoplasm antibodies; C-ANCA = classic anti-neutrophil cytoplasm antibodies; EIA = enzyme immuno-assay; IL =
interleukin; MPO = myeloperoxidase; P-ANCA = perinuclear anti-neutrophil cytoplasm antibodies; PR3 = proteinase 3; TGF = transforming
growth factor; TNF = tumor necrosis factor.
http://arthritis-research.com/content/2/4/252
Introduction
Autoantibodies to human neutrophilic granulocytes
(ANCA), described in the early 1960s, were initially
demonstrated in patients with rheumatoid arthritis, autoim-
mune neutropenia, and ulcerative colitis (reviewed in [1]).
The initial observations were by indirect immunofluores-
cence, in which the antibodies stained mainly the nuclear
or perinuclear part of human neutrophils and monocytes,
and the antibodies were therefore named ‘granulocyte-
specific antinuclear antibodies’. In the early 1980s, indi-
rect immunofluorescence studies revealed autoantibodies
to neutrophil cytoplasmic granules, visible as a distinct,
speckled pattern of staining in the cytoplasm (Fig. 1).
These antibodies were found in sera from patients with
Wegener’s granulomatosis, especially those who had
active systemic vasculitis [2]. These particular autoanti-
bodies were named ‘classic anti-neutrophil cytoplasm anti-
bodies’ (C-ANCA) [3]. They were subsequently found to
target conformational epitopes on a novel elastinolytic
serine protease in azurophil granules, proteinase 3 (PR3),
which was encoded by a gene on chromosome 19 [4].
PR3 can catabolize a number of human proteins, such as
proteoglycans, elastin, and all four subclasses of IgG
including the PR3-ANCA/PR3 complex. The latter activity
suggests that PR3-ANCA is an inefficient inhibitor of the
PR3 enzyme activity [5•]. The circulating neutrophils of
certain healthy individuals may constitutively express PR3
on their cell surface, and it has been hypothesized that this
genetic trait may predispose to small-vessel vasculitis if
self-tolerance to PR3 is overcome [6].http://arthritis-research.com/content/2/4/252
Methods of detecting ANCA
In most laboratories, screening for ANCA is done by use
of an internationally agreed indirect immunofluorescence
technique using human buffy-coat cells as substrate [7].
Sera positive for C-ANCA are further tested by direct
enzyme immunoassay (EIA) to reveal their specificity for
either purified PR3 or myeloperoxidase (MPO) as target
antigen, both of which can give rise to a C-ANCA staining
pattern [8•]. The great majority of MPO-ANCA-positive
sera, however, bind to neutrophils in a perinuclear ANCA
(P-ANCA) fashion, caused by artifactual redistribution of
MPO when the cell is permeabilized with ethanol.
Whereas the standard indirect immunofluorescence tech-
nique for detection of ANCA gave comparable results in
many different laboratories from the beginning, it was nec-
essary to set up a European multicenter study to standard-
ize direct EIA techniques for quantifying PR3-ANCA and
MPO-ANCA [9]. This multicenter study showed that both
EIA techniques could be standardized, and also that PR3
purified by several different methods was suitable for
quantifying PR3-ANCA. To optimize the clinical usefulness
of the assays, cut-off levels of PR3-ANCA and MPO-
ANCA were selected that gave a high diagnostic specificity
towards inflammatory disease control patients, distinguish-
ing vasculitis patients from patients that may be mistakenly
diagnosed as having vasculitis but have no or low levels of
ANCA [10•]. Optimum diagnostic specificity required the
use of indirect immunofluorescence and EIA in combination
[10•]. Thus, the simultaneous presence of C-ANCA and
PR3-ANCA clearly indicated systemic small-vessel vasculi-
tis, and so did the simultaneous presence of P-ANCA and
MPO-ANCA. Recently, data have been reported indicating
that a higher sensitivity may be attained without losing diag-
nostic specificity if the PR3 used for EIA is captured using a
mouse monoclonal antibody directed to an epitope that is
not recognized by human PR3-ANCA [11].
Clinical usefulness
It is now well recognized that C-ANCA/PR3-ANCA is
found in about 80% of patients with Wegener’s granulo-
matosis, and also in about 35% of patients with micro-
scopic polyangiitis, Churg–Strauss syndrome, and
renal-limited rapidly progressive glomerulonephritis [12].
The respective frequencies of P-ANCA/MPO-ANCA in
these diseases are around 15%, 50%, 40%, and 50%.
The prevalence of PR3-ANCA in patients with Wegener’s
granulomatosis depends greatly on the vasculitic disease
activity and the extent of vasculitis when the blood is
sampled. A practical consequence of finding positive C-
ANCA/PR3-ANCA results has been a great increase in
the correct diagnosis of small-vessel vasculitides [13].
Preliminary data indicate that fluctuations in PR3-ANCA
levels as measured by capture EIA may better reflect
disease activity than direct EIA methods [11]. A number of
clinical differences have been found between vasculitis in
patients with PR3-ANCA and those with MPO-ANCA
[14•]. The former have more upper-airway involvement and
are more likely to get clinical relapses of their disease than
MPO-ANCA-positive patients, who exhibit more renopul-
monary involvement and get fewer relapses. Granuloma-
tous lesions are more common in patients with
PR3-ANCA than in those with MPO-ANCA.
Relation between ANCA and focal necrotizing
vascular lesions
A characteristic feature of the small-vessel vasculitides
associated with ANCA is the focal necrotizing damage of
capillaries, venules, and sometimes arterioles [15]. The
necrosis is thought to be the result of vigorous intravascu-
lar activation of neutrophils in the microvasculature. It is
known that activation of neutrophils by certain cytokines
and chemokines, eg TNF-a, IL-1b, TGFb, and IL-8, or by
microbially derived products such as lipopolysaccharides
or enterotoxins can result in strong expression of myeloid-
cell lysosome contents such as PR3 on the cell surface of
neutrophils and monocytes [16]. IgG ANCA directed to
PR3 has been shown to act as a strong costimulatory
signal for these cells, which then release lysosomal
enzymes, oxygen radicals, and nitrogen oxide to their adja-
cent surroundings, in this case the microvascular endothe-
lium. Neutrophils at this stage of activation are inflexible
and unable to deform, and thus get stuck in the microvas-
culature [17]. Release of PR3 from neutrophils and mono-
cytes leads to detachment and cytolysis of endothelial
cells, probably through induction of apoptosis [18]. In
addition, reactive oxygen species as well as lysosomal
enzymes probably damage vascular basement mem-
branes. The characteristic focal necrotizing features of the
Figure 1
PR3-ANCA of the IgG class giving rise to a typical granular cytoplasmic
staining of neutrophils by indirect immunofluorescence. Arrow shows
negative staining of lymphocyte.Arthritis Research    Vol 2 No 4 Wiik
vascular damage can thus be caused by the abnormal
sequestration of superactivated neutrophils and mono-
cytes in the microvasculature. In this particular pathophysi-
ologic setting, the serpin superfamily protease inhibitors
including  a1-antitrypsin, monocyte/neutrophil elastase
inhibitor, antithrombin III, C1 esterase inhibitor, and others
seem to give no protection against the effects of serine
protease on vessel walls.
To get a better understanding of the pathophysiological
mechanisms of vasculitis relating to ANCA that target PR3,
it is important to reveal the potential influence of specifically
activated T cells in inducing a high level of production of
IgG PR3-ANCA, to get preliminary data about molecular
characteristics of the conformationally intact and enzymati-
cally active PR3, and to know something about the features
of the complementarity-determining regions of PR3-ANCA
molecules. This minireview addresses these issues.
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